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Abstract. Centrosome amplification plays a key role in the 
origin of chromosomal instability (CIN) during cancer devel-
opment and progression. In this study, MCF-7 breast cancer cell 
lines harboring abrogated p53 function (vMCF-7DNp53) were 
employed to investigate the relationship between induction of 
genotoxic stress, activation of cyclin-A/Cdk2 and Aurora-A 
oncogenic signalings and development of centrosome amplifi-
cation. Introduction of genotoxic stress in the vMCF-7DNp53 cell 
line by treatment with hydroxyurea (HU) induced centrosome 
amplification that was mechanistically linked to Aurora-A 
kinase activity. In cells carrying defective p53, the develop-
ment of centrosome amplification also occurred following 
treatment with another DNA damaging agent, methotrexate. 
Importantly, we demonstrated that Aurora-A kinase-induced 
centrosome amplification was mediated by Cdk2 kinase since 
molecular inhibition of Cdk2 activity by SU9516 suppressed 
Aurora-A centrosomal localization and consequent centro-
some amplification. In addition, we employed vMCF-7DRaf-1 
cells that display high levels of endogenous cyclin-A and 
demonstrated that molecular targeting of Aurora-A by 
Alisertib reduces cyclin-A expression. Taken together, these 
findings demonstrate a novel positive feed-back loop between 
cyclin-A/Cdk2 and Aurora-A pathways in the development 
of centrosome amplification in breast cancer cells. They also 
provide the translational rationale for targeting ‘druggable 
cell cycle regulators’ as an innovative therapeutic strategy to 
inhibit centrosome amplification and CIN in breast tumors 
resistant to conventional chemotherapeutic drugs.
Introduction
The progression of aggressive breast cancer is characterized by 
genomic instability leading to multiple genetic defects, pheno-
typic heterogeneity, chemoresistance and poor outcome (1,2). 
An imbalance between oncogene and tumor suppressor activi-
ties plays an important role in the onset of breast cancer through 
the inactivation of G1/S and/or G2/M cell cycle checkpoints, 
which normally ensure the orderly progression of cell cycle 
events (3). In normal cells, checkpoint activation in response 
to DNA damage is mediated by p53 activation and inhibi-
tion of Cdk2 activity leading to cell cycle arrest (4-6). The 
centrosome has been implicated in the pathogenesis of cancer 
through the development of multipolar mitotic spindles leading 
to chromosomal instability and tumor cell heterogeneity (7,8). 
The centrosome is the major microtubule-organizing center 
of the cell and is duplicated once during a normal cell cycle 
to give rise to two centrosomes that function as the spindle 
poles during mitosis (3). Therefore, tight coordination between 
centrosome duplication and DNA replication cycles is essen-
tial to ensure equal segregation of sister chromatids during cell 
division. In cancer, loss of coordination between the centro-
some and DNA cycles leads to centrosome amplification, 
increased frequency of multipolar mitoses, and consequent 
chromosomal instability (5,6,9,10). p53 and cyclin-A/Cdk2 
play an important role in coordinating centrosome duplication 
with cell cycle events. In mouse model studies, loss of p53 by 
gene targeting and gain-of-function p53 mutations resulted 
in the development of centrosome amplification and aberrant 
mitoses (5,6,11). Furthermore, cyclin-A has been demonstrated 
to be a key regulator of the centrosome cycle (12,13), and p53 
mutations associated with cyclin-A overexpression syner-
gistically increase the frequency of centrosome defects (14). 
Aurora-A mitotic kinase is a critical Ser/Thr protein kinase 
that also controls centrosome maturation and duplication and 
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regulates spindle formation for appropriate chromosomal 
segregation during normal mitosis (15). In cancer cells, 
overexpression of Aurora-A kinase promotes centrosome 
amplification and chromosomal instability (CIN), thus confer-
ring tumor cell heterogeneity associated with acquired drug 
resistance and poor outcome (16). Aurora-A is overexpressed 
in human breast tumors and is associated with an invasive 
basal-like phenotype and poor prognosis (17). Aurora-A 
exerts a direct effect on oncogenic transformation in vitro 
and in vivo through increased p53 degradation and inhibition 
of apoptosis through activation of the PI3K/AKT pathway 
leading to chemoresistance (18). In human breast cancer, the 
mechanistic relationship between deregulated activity of the 
cyclin-A/Cdk2 complex and Aurora-A kinase in the induc-
tion of centrosome amplification has not been investigated. 
To establish the molecular mechanisms linking genotoxic 
stress, G1/S checkpoint and Aurora-A kinase activity to the 
centrosome duplication cycle, we studied the effect of drugs 
inducing genotoxic stress in breast tumor-derived cell lines 
with abrogated p53 function as previously described (5,6). Our 
results demonstrated that induction of genotoxic stress induces 
centrosome amplification through stabilization and activation 
of Aurora-A kinase mediated by Cdk2 oncogenic signaling in 
breast cancer cells.
Materials and methods
Human breast cancer cell lines. The human breast cancer 
cell line MCF-7 was obtained from ATCC (Manassas, VA, 
USA). The MCF-7 cells carrying a dominant-negative p53 
mutant (vMCF-7DNp53) or overexpressing a constitutive active 
Raf-1 oncoprotein (vMCF-7DRaf-1) were generated as previously 
described (5,6,19,20).
Induction of genotoxic stress. To investigate the relationship 
between centrosome amplification and G1/S checkpoint activa-
tion, cell lines were plated at a density of 3x105. After 48 h, 
cells were treated with 2 mM hydroxyurea (HU) or 1 µM 
methotrexate for 48 h to induce genotoxic stress and centro-
some amplification.
Treatment of cancer cells with small‑molecule inhibitors of 
Cdk2 and Aurora‑A. To inhibit Cdk2 or Aurora-A kinase 
activity, cancer cells were treated with 1 µM SU9516 or 1 µM 
Alisertib, and the resulting cellular phenotype was analyzed 
by immunofluorescence and immunoblotting.
Indirect immunofluorescence and immunoblotting. For indi-
rect immunofluorescence and protein expression analyses, 
breast cancer cells were treated as previously described 
(5,6,19,20). Antibodies employed in this study were the 
following: Aurora-A (Cell Signaling Technology, Inc., Beverly, 
MA, USA); cyclin A (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA) and β-actin (Sigma, St. Louis, MO, USA). 
Centrin antibody (20H5) was kindly provided by Dr Salisbury's 
Laboratory (Mayo Clinic, Rochester, MN, USA).
Construction of the shRNA Aurora‑A vector. The PSSH1 
shRNA suppression plasmid contains the H1 RNA poly-
merase III-dependent promoter for the generation of shRNA 
molecules. shRNA oligos directed against the 39 UTR of 
Aurora A (TAGGGATTTGCTTGG-GATA) were annealed 
and cloned into the BglII/HindIII cloning site at the 3' end 
of the RNA polymerase III-dependent H1 RNA promoter 
driven vector. Clones containing the insert were identified and 
sequenced to ensure fidelity.
Results
To establish the mechanistic linkage between Cdk2 and 
Aurora-A kinase oncogenic signalings in the induction of 
centrosome amplification, we employed MCF-7 breast cancer 
cells harboring abrogated p53 function (MCF-7DNp53). The 
centrosome phenotype was characterized employing antibodies 
directed against the centrosomal protein centrin and the mitotic 
kinase Aurora-A. Treatment of MCF-7DNp53 cells with HU for 
48 h resulted in centrosome amplification characterized by 
centriole overduplication (Fig. 1A) as previously described (5). 
Importantly, the amplified centrosomes displayed robust 
Aurora-A co-localization suggesting that Aurora-A kinase 
activity may induce centrosome amplification after genotoxic 
stress (Fig. 1B). To investigate whether Aurora-A kinase activity 
plays a direct role in the induction of centrosome amplification, 
we treated MCF-7DNp53 cells with HU and shRNA targeting 
Aurora-A for 48 h. Following knockdown of Aurora-A, centro-
some amplification failed to occur after genotoxic stress, and 
remarkably a normal centrosome phenotype was rescued in 
MCF-7DNp53 cells (Fig. 1C).  These results demonstrate the 
causal role of Aurora-A kinase activity in the induction of 
centrosome amplification following genotoxic stress.
Next, we investigated the mechanistic linkage between 
Cdk2 and Aurora-A kinase activity in the induction of centro-
some amplification following genotoxic stress in MCF-7DNp53 
and parental MCF-7 cells. We previously demonstrated that 
abrogation of p53 function leads to deregulated activity of the 
cyclin-A/Cdk2 complex resulting in induction of centrosome 
amplification (5,6). In this study, we established an in vitro 
functional assay where MCF-7DNp53 and parental MCF-7 cells 
were treated with methotrexate, a genotoxic agent commonly 
employed in the adjuvant setting of breast cancer. In order to 
determine the concentration of methotrexate that will inhibit 
DNA replication and induce genotoxic stress, we performed 
dose response and time course experiments with MCF-7 and 
MCF-7DNp53 cells. Our experiments established that incubation 
for 48 h with 1 µM methotrexate induced a G1/S arrest of the 
cell cycle by FACS analysis (data not shown). To determine 
the effect of methotrexate on the development of centrosome 
amplification and Aurora-A centrosomal localization, we incu-
bated MCF-7 and MCF-7DNp53 cells with 1 µM methotrexate for 
48 h and analyzed the centrosome phenotype using antibodies 
directed against the proteins centrin and Aurora-A. As previ-
ously demonstrated, MCF-7 cells retained a normal centrosome 
phenotype while vMCF-7DNp53 cells developed centrosome 
amplification (only centrosomes from the vMCF-7DNp53 cells 
are shown in Fig. 2). Genotoxic stress-induced centrosome 
amplification was associated with an increase in Aurora-A 
centrosomal localization as we already demonstrated in Fig. 1B. 
This effect of methotrexate on centrosome amplification and 
Aurora-A centrosomal localization was blocked by incubation 
for 48 h with the small-molecule inhibitor of Cdk2 activity, 
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SU9516 (Fig. 2). These results indicated that Aurora-A kinase 
activity is downstream to Cdk2 signaling in the induction of 
centrosome amplification. To investigate at the mechanistic 
level the role of Cdk2 kinase in the activation of Aurora-A-
induced centrosome amplification, we engineered vMCF-7DNp53 
cells overexpressing an Aurora-A lentivector (vMCF-7DNp53/
Aurora-A). vMCF-7DNp53/Aurora-A cells displayed centrosome 
amplification without induction of genotoxic stress, confirming 
the causal role of aberrant Aurora-A kinase activity in inducing 
centriole over-duplication (Fig. 2). Importantly, treatment 
of vMCF-7DNp53/Aurora-A cells with 1 µM SU9516 for 48 h 
reduced Aurora-A centrosomal localization that was linked 
to suppression of centrosome amplification (Fig. 2). Since we 
previously demonstrated that Cdk2 controls the centrosome 
duplication cycle through interaction with cyclin-A (5), we 
employed a variant MCF-7 cell line overexpressing a consti-
tutive active Raf-1 oncoprotein (vMCF-7DRaf-1) that displays 
high levels of endogenous cyclin-A (20). To investigate the 
presence of a positive feed-back loop between cyclin-A/Cdk2 
and Aurora-A oncogenic signalings, we treated MCF-7 and 
vMCF-7DRaf-1 cells with a novel Aurora-A inhibitor (Alisertib) 
to assess the expression of cyclin-A (Fig. 3). Importantly, 
treatment with Alisertib induced the reduction  in cyclin-A 
expression in vMCF-7DRaf-1 cells demonstrating that Aurora-A 
kinase may modulate cyclin-A/Cdk2 activity during cell cycle 
progression. Taken together, these findings demonstrate at the 
mechanistic level a novel interplay between cyclin-A/Cdk2 and 
Aurora-A oncogenic signalings in the development of centro-
some amplification in breast cancer cells. 
Discussion
Deregulation of cell cycle checkpoints, centrosome amplifica-
tion and induction of CIN are hallmarks of breast cancer (10). 
CIN represents a major problem in the management of 
breast cancer patients due to the generation of tumor clonal 
heterogeneity, which in turn may facilitate the development 
of chemoresistance and tumor progression (21). However, 
molecular mechanisms associated with the development 
of CIN are poorly understood in breast cancer. Several 
studies suggest that deregulation of the centrosome cycle 
leading to centrosome amplification may lead to the devel-
opment of CIN through the formation of multipolar mitotic 
spindles and unequal chromosome segregation (3,10,22). 
The tumor-suppressor gene p53, mutated in >50% of human 
cancers (23), plays an important role in the maintenance of 
Figure 1. Induction of centrosome amplification following genotoxic stress. (A) Immunofluorescence analysis showing duplicated centrosomes in vMCF-7DNp53 
cells. (B) Centrosome amplification after hydroxyurea (HU) treatment in vMCF-7DNp53 cells. (C) Inhibition of centrosome amplification after HU and shRNA 
Aurora-A treatment. The centrosome protein centrin was labeled in green, the mitotic kinase Aurora-A was labeled in red and DNA was labeled in blue with 
Hoechst dye.
Figure 2. Inhibition of Cdk2 kinase activity restores a normal centrosome 
phenotype. Immunofluorescence analysis showing a centrosome phenotype in 
vMCF-7DNp53 and vMCF-7DNp53-overexpressing Aurora-A cancer cells following 
treatment with methotrexate and SU9516. The centrosome protein centrin was 
labeled in red and the mitotic kinase Aurora-A was labeled in green.
Figure 3. Inhibition of Aurora-A kinase activity reduces cyclin-A expression. 
Immunoblot analysis of parental and MCF-7 cells overexpressing a constitu-
tive active Raf-1 oncoprotein (vMCF-7DRaf-1) showing that molecular targeting 
of Aurora-A with Alisertib reduces cyclin A expression in vMCF-7DRaf-1 cells.
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centrosome homeostasis since loss of p53 function can lead 
to centrosome defects (5,6). Furthermore, the Cdk2/cyclin-A 
complex has also been implicated in the control of centrosome 
duplication (5,6,12), and changes in their expression correlates 
with centrosome amplification (24), suggesting an interplay 
between the p53 and cdk2/cyclin-A pathways in coordinating 
centrosome duplication with other cell cycle events. Moreover, 
the centrosome duplication cycle is also regulated by the 
mitotic kinase Aurora-A (25). Aberrant Aurora-A kinase 
activation induces centrosome amplification and CIN in solid 
tumors (16). However, whether or not deregulated function of 
the cyclin-A/Cdk2 complex induces centrosome amplifica-
tion through aberrant activation of Aurora-A kinase has not 
been established. In the present study, we investigated the 
mechanistic linkage between cyclin-A/Cdk2 and Aurora-A 
oncogenic signalings in the development of centrosome ampli-
fication in human breast cancer cell models. We employed 
vMCF-7DNp53 cells that display a deregulated activity of the 
cyclin-A/Cdk2 complex and develop centrosome amplification 
after genotoxic stress (5,6). Following induction of genotoxic 
stress, vMCF-7DNp53 cells developed centrosome amplifica-
tion that was functionally linked to an increase in Aurora-A 
centrosomal localization. Aurora-A played a causal role in the 
induction of centrosome amplification, since suppression of 
Aurora-A expression restored a normal centrosome phenotype. 
Importantly, we demonstrated that Aurora-A kinase-induced 
centrosome amplification was mediated by Cdk2 activity since 
molecular targeting of Cdk2 suppressed Aurora-A centrosomal 
localization and the consequent centrosome amplification. 
Moreover, we employed vMCF-7DRaf-1 cells that display high 
levels of endogenous cyclin-A, and we demonstrated that 
molecular targeting of Aurora-A reduces cyclin-A expression. 
In conclusion, these findings highlight a novel positive feed-
back loop between cyclin-A/Cdk2 and Aurora-A pathways in 
the development of centrosome amplification in breast cancer 
cells. They also provide the operational rationale for targeting 
‘druggable cell cycle regulators’ as an innovative therapeutic 
strategy to inhibit centrosome amplification and CIN in breast 
tumors resistant to conventional chemotherapeutic drugs.
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